Almirall puts on the block ThermiGen, its aesthetics subsidiary in the US
Almirall habría puesto en venta ThermiGen, su filial de estética en EEUU
Intel ID : 264900
|
||||
| Intel ID | 264900 | ||
| Value | ND | ||
| Native Currency | Euro (EUR) | ||
|
Financial Data - Almirall
(31 Dec 2022) |
Revenue: EUR 895,52m EBITDA: EUR 187,28m Net Debt: EUR 5.791,57m People: 1846 |
||
| Date |
 |
||
| Country |  |
||
| Region | |||
| Continent | |
||
| Geography | |
||
| Subsector (Old TTR Sectors) |
|
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.05.01 Aesthetic Medicine 30 Healthcare / 30.05 Specialized Medicine |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Seller
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.